Bright Minds Biosciences DRUG Stock
Bright Minds Biosciences Price Chart
Bright Minds Biosciences DRUG Financial and Trading Overview
| Bright Minds Biosciences stock price | 65.13 USD |
| Previous Close | 60.66 USD |
| Open | 60.92 USD |
| Bid | 62.68 USD x 100 |
| Ask | 61.3 USD x 100 |
| Day's Range | 60.1 - 63.81 USD |
| 52 Week Range | 23.18 - 123.75 USD |
| Volume | 333.68K USD |
| Avg. Volume | 274.41K USD |
| Market Cap | 622.97M USD |
| Beta (5Y Monthly) | -0.11 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.41 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 165.39 USD |
DRUG Valuation Measures
| Enterprise Value | 313.36M USD |
| Trailing P/E | N/A |
| Forward P/E | -7.442801 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | N/A |
| Price/Book (mrq) | 2.860522 |
| Enterprise Value/Revenue | N/A |
| Enterprise Value/EBITDA | N/A |
Trading Information
Bright Minds Biosciences Stock Price History
| Beta (5Y Monthly) | -0.11 |
| 52-Week Change | 123.92% |
| S&P500 52-Week Change | 22.66% |
| 52 Week High | 123.75 USD |
| 52 Week Low | 23.18 USD |
| 50-Day Moving Average | 80.54 USD |
| 200-Day Moving Average | 72.82 USD |
DRUG Share Statistics
| Avg. Volume (3 month) | 274.41K USD |
| Avg. Daily Volume (10-Days) | 493.47K USD |
| Shares Outstanding | 9.81M |
| Float | 5.13M |
| Short Ratio | 3.45 |
| % Held by Insiders | 12.02% |
| % Held by Institutions | 92.81% |
| Shares Short | 805.67K |
| Short % of Float | 10.66% |
| Short % of Shares Outstanding | 8.21% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor | 1:5 |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | September 30, 2025 |
| Most Recent Quarter (mrq) | March 31, 2026 |
| Next Fiscal Year End | September 30, 2026 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | 0% |
| Gross Margin | 0% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -10.43% |
| Return on Equity (ttm) | -15.018% |
Income Statement
| Revenue (ttm) | N/A |
| Revenue Per Share (ttm) | N/A |
| Quarterly Revenue Growth (yoy) | N/A |
| Gross Profit (ttm) | N/A |
| EBITDA | N/A |
| Net Income Avi to Common (ttm) | -27353518 USD |
| Diluted EPS (ttm) | -2.44 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 309.69M USD |
| Total Cash Per Share (mrq) | 31.56 USD |
| Total Debt (mrq) | 82.13K USD |
| Total Debt/Equity (mrq) | 0.03 USD |
| Current Ratio (mrq) | 81.481 |
| Book Value Per Share (mrq) | 22.19525 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -19833944 USD |
| Levered Free Cash Flow (ttm) | -13104564 USD |
Profile of Bright Minds Biosciences
| Country | United States |
| State | NY |
| City | New York |
| Address | 19 Vestry Street |
| ZIP | 10013 |
| Phone | 647 865 8622 |
| Website | https://brightmindsbio.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 26 |
Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio includes 5-HT2 Receptors, which are serotonin agonists for epilepsy and neuropsychiatric disorders; and BMB-101, which has completed phase 1 trial for undisclosed seizure disorder and is in phase 2 clinical trials for the developmental and epileptic encephalopathies and absence epilepsies. The company also develops BMB-201 and BMB-202 for the treatment of neuropsychiatric and neurology indications; and BMB-105, a 5-HT2C agonist to treat Prader Willi Syndrome. Bright Minds Biosciences Inc. has a collaboration with Firefly Neuroscience, Inc. to provide an analysis of the electroencephalogram (EEG) data in the Company's BREAKTHROUGH study. The company was founded in 2017 and is headquartered in New York, New York.
Q&A For Bright Minds Biosciences Stock
What is a current DRUG stock price?
Bright Minds Biosciences DRUG stock price today per share is 65.13 USD.
How to purchase Bright Minds Biosciences stock?
You can buy DRUG shares on the Tech Market Small exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Bright Minds Biosciences?
The stock symbol or ticker of Bright Minds Biosciences is DRUG.
Which industry does the Bright Minds Biosciences company belong to?
The Bright Minds Biosciences industry is Biotechnology.
How many shares does Bright Minds Biosciences have in circulation?
The max supply of Bright Minds Biosciences shares is 9.81M.
What is Bright Minds Biosciences Price to Earnings Ratio (PE Ratio)?
Bright Minds Biosciences PE Ratio is now.
What was Bright Minds Biosciences earnings per share over the trailing 12 months (TTM)?
Bright Minds Biosciences EPS is -2.41 USD over the trailing 12 months.
Which sector does the Bright Minds Biosciences company belong to?
The Bright Minds Biosciences sector is Healthcare.
Bright Minds Biosciences DRUG included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
|
|
{{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
US Tech Composite
IXIC
US
|
25587.04 USD — |
-2.21
|
13.85B USD — | 25513.26 USD — | 25882.57 USD — | — - | 13.85B USD — |
|
US Tech Health Care
IXHC
US
|
1184.66 USD — |
+0.75
|
— — | 1174.72 USD — | 1192.68 USD — | — - | — — |
- {{ link.label }} {{link}}